Trump and terror have negative effect on overseas markets

Published 23-MAR-2017 10:59 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

US markets tended to plateau after the sharp fall at the end of last week. That said, there is increasingly negative sentiment surrounding President Trump’s ability to deliver on fiscal changes that he has flagged.

Undermining confidence was the seemingly increasing likelihood that Trump’s health care plan is under threat. This would cast doubt over his ability to deliver other important pro-business promises such as lowering taxes, increasing infrastructure spending and dispensing with certain banking reforms.

The Dow was down nearly 100 points in early trading, but recovered most of that ground to close at 20,661 points.

The NASDAQ defied negative sentiment, increasing 0.5% on the back of strong gains by Microsoft and Apple to close at 5821 points.

European banks weighed heavily on the FTSE 100 as Trump tremors reverberated across continents. Market commentators saw this as having a more significant impact on the market than the terror attack at Parliament house, as only sketchy details were available prior to the London Stock Exchange closing.

The FTSE 100 came off 0.7% to close at 7324 points.

The DAX and the Paris CAC 40 fell 0.5% and 0.2% respectively to close at 11,904 points and 4994 points.

It was another poor night for oil as it fell from the previous close of US$48.24 per barrel to a low of US$47.01 per barrel in mid-morning trading. While most of this ground was recovered prior to the market closing it still finished in negative territory.

Gold continues to eke out small gains, closing at US$1252 per ounce, representing an increase of 0.2%. Whether there could be support for the precious metal on the back of the London terror attack remains to be seen.

Elsewhere on the commodities front it was iron ore that was once again front and centre, falling a further 3% to circa US$85 per tonne, suggesting another dour day for the likes of Rio Tinto, BHP Billiton and Fortescue Metals Group.

An outstanding rally in the lead price sparked the most interest. It increased 4.6% from the previous day’s close of US$1.02 per pound to US$1.07 per pound, a level it hasn’t traded at since mid-February when it experienced a sharp fall of approximately 6% in a matter of days.

Last night’s increase coincided with a substantial decline in 30 day LME Lead Warehouse stock levels, suggesting that investors may be warming to the positive underlying supply demand dynamics which aren’t all that dissimilar to the fundamentals that have driven the zinc price over the last 12 months.

On that note, zinc also performed well, increasing circa 1.4% to US$1.28 per pound.

Copper made modest ground while nickel pulled back slightly.

The Australian dollar came under pressure, slipping .04% to close at US$0.767.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X